Reimbursement Options in Canada
TAKHZYRO® (lanadelumab injection) is indicated for routine prevention of attacks of hereditary angioedema (HAE) in adolescents and adults. TAKHZYRO is not intended for acute treatment of HAE attacks.
Both public and private reimbursement options for adult patients†
TAKHZYRO is available in pre-filled syringe (PFS) formats in British Columbia, Alberta, Saskatchewan, Manitoba, Ontario, New Brunswick, Nova Scotia, Newfoundland, Quebec, and Prince Edward Island. Patients on vial will be provided PFS as it becomes available in each province, with no extra enrolment required. OnePath® will ensure patients are trained on the PFS format prior to receiving it.
Reimbursement questions?
Contact the OnePath® Patient Support Program for assistance.
Phone: 1‑844‑MY1‑PATH (1‑844‑691‑7284)Monday through Friday, 8 a.m. to 8 p.m. EST
Fax: 1‑844‑951‑7284
Email: support@onepathprogram.ca
Consult the product monograph at https://www.takeda.com/en-ca/takhzyropm for contraindications, warnings, precautions, adverse reactions, interactions, dosing, and conditions of clinical use. The product monograph is also available by calling 1-800-268-2772.
To find out more about FIRAZYR reimbursement
Click here- Each province and territory has specific coverage criteria. Contact OnePath® for more details concerning the reimbursement process.